...Hello. Welcome, everybody, to Recursion's Q2 2025 earnings call. My name is Chris Gibson. I'm the Co-Founder and CEO of Recursion. I'm excited to share with you today some of the latest updates on our company, as we drive forward to decode biology. We've been talking for the last nine months since the business combination with Exscientia about the Recursion OS 2.0. I want to start there today and tell you a little bit about the way that we're bringing together the incredible components from both Exscientia and Recursion and building new components of the OS in order to drive forward our mission. At Recursion, we base everything off of proprietary fit-for-purpose data, whether it's data we generate in-house or data that we pull from partners. We're not just generating data to help discover targets or to help translate programs or to help with clinical trials, we're building a true end-to-end capability, from target discovery all the way through to clinical trial simulation. We're really,...
